Vascularized Composite Allograft Rejection Is Delayed by Intrajejunal Treatment with Donor Splenocytes without Concomitant Immunosuppressants

Figure 3

One-way MLR demonstrating significant donor-specific hyporesponsiveness conferred by seven consecutive daily intrajejunal doses of 5×10⁷ LBN FDS. “*” 𝑃<0.05; “NS” 𝑃<0.05.